Ruxolitinib for Steroid-refractory GVHD

NCT02997280 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Graft Vs Host Disease

Interventions

DRUG: Ruxolitinib Oral Tablet

Sponsor

St. Petersburg State Pavlov Medical University

Collaborators

[object Object]